Sagimet Biosciences (STU:0O2) Price-to-Operating-Cash-Flow: (As of Jul. 13, 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
38 GF Score
Price €6.44
GF Value €5.69
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Price-to-Operating-Cash-Flow?

As of today (2026-07-13), Sagimet Biosciences's share price is €6.44. Sagimet Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.05. Hence, Sagimet Biosciences's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Sagimet Biosciences's Price-to-Operating-Cash-Flow or its related term are showing as below:

STU:0O2's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 21.435
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Sagimet Biosciences's Cash Flow from Operations per share for the three months ended in Mar. 2026 was €-0.23. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.05.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -8.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -22.80% per year.

During the past 7 years, Sagimet Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -8.50% per year. The lowest was -69.10% per year. And the median was -21.90% per year.

Sagimet Biosciences Price-to-Operating-Cash-Flow Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Price-to-Operating-Cash-Flow Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0O2 vs EDIT, AUTL, FBRX: Price-to-Operating-Cash-Flow Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences Price-to-Operating-Cash-Flow vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Price-to-Operating-Cash-Flow falls into.


STU:0O2
38GF Score
Sagimet Biosciences Inc STU:0O2
Price-to-Operating-Cash-Flow is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Price-to-Operating-Cash-Flow Calculation

Sagimet Biosciences's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=6.44/-1.052
=

Sagimet Biosciences's Share Price of today is €6.44.
Sagimet Biosciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?

Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued. The current stock price of €6.44 is trading 13.2% above its estimated GF Value™ of €5.69. GuruFocus considers Sagimet Biosciences to be Modestly Overvalued.

Key valuation signals for STU:0O2:

  • Price-to-Operating-Cash-Flow:
  • GF Value™: €5.69 vs. price of €6.44 (13.2% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score

Get the complete analysis for STU:0O2

Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.44
Price
€5.69
GF Value